Cargando…
FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer
BACKGROUND: Pancreatic Cancer is one of the most lethal cancers, with less than 8% of patients surviving 5 years following diagnosis. The last 40 years have seen only small incremental improvements in treatment options, highlighting the continued need to better define the cellular and molecular path...
Autores principales: | Davidson, Catherine, Taggart, David, Sims, Andrew H., Lonergan, David W., Canel, Marta, Serrels, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643373/ https://www.ncbi.nlm.nih.gov/pubmed/36138073 http://dx.doi.org/10.1038/s41416-022-01966-5 |
Ejemplares similares
-
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
por: Canel, Marta, et al.
Publicado: (2020) -
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017) -
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
por: Serrels, Alan, et al.
Publicado: (2015) -
FAK and talin: Who is taking whom to the integrin engagement party?
por: Serrels, Bryan, et al.
Publicado: (2012) -
Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice
por: Alexopoulou, Annika N, et al.
Publicado: (2017)